Morgan Stanley Moleculin Biotech, Inc. Transaction History

Morgan Stanley

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Aug 16, 2024	BUY	$0.41 - $0.86 $2,596 - $5,447	6,334 New	6,334 $5,000
Q1 2023 May 15, 2023	SELL	$0.9 - $1.34 $4 - $6	-5 Reduced 0.08%	6,334 $6,000
Q4 2022 Feb 14, 2023	BUY	$0.85 - $16.65 $277 - $5,444	327 Added 5.44%	6,339 $6,000
Q3 2022 Nov 14, 2022	BUY	$1.15 - $17.4 $13 - $208	12 Added 0.2%	6,012 $6,000
Q2 2022 Oct 27, 2022	SELL	$1.19 - $2.0 $29 - $50	-25 Reduced 0.41%	6,000 $9,000
Q2 2022 Aug 15, 2022	SELL	$1.19 - $2.0 $29 - $50	-25 Reduced 0.41%	6,000 $9,000
Q1 2022 Oct 27, 2022	BUY	$1.23 - $1.9 $30 - $47	25 Added 0.42%	6,025 $11,000
Q1 2022 May 13, 2022	BUY	$1.23 - $1.9 $29 - $45	24 Added 0.4%	6,025 $11,000
Q4 2021 Feb 14, 2022	BUY	$1.64 - $2.83 $1 - $2	1 Added 0.02%	6,001 $11,000
Q3 2021 Nov 15, 2021	BUY	$2.7 - $3.59 $16,200 - $21,540	6,000 New	6,000 $18,000

3.35K

Ticker MBRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 28,606,700
Market Cap $48.6M
Description
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs....

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.